TX-ZILLIANT
19.4.2022 13:02:09 CEST | Business Wire | Press release
Zilliant , the industry leader in intelligent end-to-end pricing solutions and sales guidance software, today announced Next-Generation Price IQ® , the next giant leap for its market-leading B2B price optimization solution.
Inflation has become the new business reality, exacerbated by supply chain turmoil, increased competition, and dramatic swings in both demand and inventory availability. As a result, B2B companies need a faster, more powerful approach to pricing that maintains market alignment while generating prices that are easily explainable and defensible.
Next-Generation Price IQ® delivers huge advances in performance, with a 10x improvement in AI-based optimization speeds. Now, businesses can quickly respond to rapidly changing business dynamics and market changes while providing unprecedented price transparency to sales teams.
“Leading the market in price optimization for two decades has revealed one critical truth: If sales reps don’t understand how a price is generated, they are unlikely to use it,” said Zilliant President and Chief Executive Officer Greg Peters. “That’s why I’m thrilled to announce today that Next-Generation Price IQ® provides a way to keep prices competitive amid near-constant change while also providing a pragmatic means to leverage AI with a crystal-clear view into how prices were derived.”
Other B2B pricing solutions make it impossible to understand how pricing was derived by tucking parameters, complex AI, and formulas out of sight and out of reach for users, or they generate pricing using strict rules that break as complexity increases. These methods fail to address volatile and competitive B2B markets.
In stark contrast, Next-Generation Price IQ® offers a transparent, proven and pragmatic pricing solution using data science and AI that’s both sophisticated and flexible. Most importantly, Zilliant is helping embroiled B2B companies navigate a supply-constrained, pandemic-disrupted, and inflationary time to meet and exceed their margin and revenue goals.
Zilliant’s next generation of price optimization empowers pricing teams to:
- Conduct goal-seeking, what-if scenarios to align business goals with pricing strategies
- Enforce rational price relationships such as minimum margin requirements and good-better-best product relationships
- Simultaneously visualize the predicted margin, revenue and volume impacts for various what-if scenarios before publishing optimized prices
- View precisely how the optimization engine produced each price, drill into each optimized price, view the associated transactions with inline analytics, make adjustments, and see how price changes will impact revenue and profit
- Immediately publish prices into CRM, CPQ, ERP, eCommerce or any other commercial system
No other price optimization solution in B2B can measure price elasticity, enforce rational price relationships, and conduct goal-seeking what-if scenarios in B2B. Where other applications use sequential rules or if-then statements, Next-Generation Price IQ® takes full advantage of constraint-based optimization to simultaneously account for business rules and price relationship requirements. Additionally, Zilliant is the only price optimization and management software company to offer a dedicated customer success team of industry, pricing, and data science experts to act as a strategic partner, delivering continuous value, change management guidance and precise measurement of adoption metrics, margin and revenue drivers, KPI trends, and pricing opportunity analyses.
Customers have reported a 10x ROI in less than a year with Zilliant’s price optimization solution; Next-Generation Price IQ® can be up and running in 90 days and lowers overall cost by supporting multiple pricing models and scenario templates, enabling simultaneous optimization of multiple lines of business within the same instance.
To learn more about Next-Generation Price IQ® , visit https://www.zilliant.com/products/priceiq .
About Zilliant
Zilliant powers intelligent commerce for B2B companies by connecting their commercial strategies with effective execution. Our industry-leading price optimization and management and sales guidance software enables profitable growth by transforming the way our customers use data to price and sell in traditional and digital channels. Zilliant’s data science, cloud-native software and passion for customer success delivers the highest ROI, fastest time to value and highest customer satisfaction. Learn more about how Zilliant helps power intelligence commerce at www.zilliant.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom